TAT Technologies Q3 2026 Results: Record Growth, but Valuation and Cash Conversion Concerns Persist

What happened

TAT Technologies released Q3 2026 results showing record quarterly and nine-month revenue, gross margin, and adjusted EBITDA, with revenue up 20.2%, adjusted EBITDA up 60.9%, and diluted EPS up 57.8% year-over-year. The press release highlights continued operational momentum, but it follows a period where the company already traded at premium multiples (P/E ~33x, EV/EBITDA ~28x) that assume sustained growth and improving cash conversion. Prior analysis flagged that free cash flow has historically lagged earnings due to working-capital intensity, and despite recent improvements, TTM free cash flow remains modestly negative. The record results may reinforce the growth narrative, but investors should scrutinize whether the improved earnings are translating into cash generation and whether the backlog is converting efficiently. Given the stock is up 76% over the past 12 months, the strong quarter is likely already partly priced in, and the key question is whether these results lead to a sustainable inflection in free cash flow or if they simply extend the earnings multiple without underlying cash support.

Implication

The record Q3 results confirm TAT's ability to grow revenue and expand margins in a favorable aerospace aftermarket environment, supporting the bull case for its niche MRO and thermal management business. However, the stock's valuation at ~34x earnings and 28x EBITDA leaves little room for error, and the company has repeatedly raised equity, diluting shareholders, to fund growth and working capital. The critical test is whether the improving adjusted EBITDA can convert into meaningful free cash flow, as the company's history shows large swings and negative cumulative FCF from 2021-2024. Investors should monitor backlog conversion, inventory and receivables management, and any further equity issuance, as these will determine if the operational success translates into shareholder value. Until there is clear evidence of sustained positive free cash flow and no further dilution, the risk-reward remains unattractive for new money, and a WAIT stance remains appropriate.

Thesis delta

The thesis remains unchanged: TAT continues to execute operationally, but the market already prices in a significant premium. The record quarter supports revenue and margin momentum, yet the persistent gap between earnings and free cash flow and repeated dilution keep the risk-reward unappealing. No change to the WAIT rating.